Page last updated: 2024-10-20

selenic acid and DDPAC

selenic acid has been researched along with DDPAC in 1 studies

Selenic Acid: A strong dibasic acid with the molecular formula H2SeO4. Included under this heading is the acid form, and inorganic salts of dihydrogen selenium tetraoxide.

Research Excerpts

ExcerptRelevanceReference
"Behavioural variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder often neuropathologically associated with the accumulation of abnormally hyperphosphorylated tau, for which there is currently no disease-modifying treatment."2.94A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. ( Ahmed, RM; Brodtmann, A; Bush, AI; Churilov, L; Darby, D; Hovens, CM; Kalincik, T; Malpas, CB; O'Brien, TJ; Piguet, O; Velakoulis, D; Vivash, L; Walterfang, M, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Vivash, L1
Malpas, CB1
Churilov, L1
Walterfang, M1
Brodtmann, A1
Piguet, O1
Ahmed, RM1
Bush, AI1
Hovens, CM1
Kalincik, T1
Darby, D1
Velakoulis, D1
O'Brien, TJ1

Trials

1 trial available for selenic acid and DDPAC

ArticleYear
A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia.
    BMJ open, 2020, 11-16, Volume: 10, Issue:11

    Topics: Australia; Clinical Trials, Phase II as Topic; Double-Blind Method; Frontotemporal Dementia; Humans;

2020